MA41562B1 - Agonistes d'apj 4-hydroxy-3-(heteroaryl)pyridine-2-one a utiliser dans le traitement de troubles cardio-vasculaires - Google Patents

Agonistes d'apj 4-hydroxy-3-(heteroaryl)pyridine-2-one a utiliser dans le traitement de troubles cardio-vasculaires

Info

Publication number
MA41562B1
MA41562B1 MA41562A MA41562A MA41562B1 MA 41562 B1 MA41562 B1 MA 41562B1 MA 41562 A MA41562 A MA 41562A MA 41562 A MA41562 A MA 41562A MA 41562 B1 MA41562 B1 MA 41562B1
Authority
MA
Morocco
Prior art keywords
agonists
heteroaryl
pyridine
hydroxy
treatment
Prior art date
Application number
MA41562A
Other languages
English (en)
Other versions
MA41562A1 (fr
Inventor
James A Johnson
Soong-Hoon Kim
R Michael Lawrence
Michael C Myers
Hannguang J Chao
Monique Phillips
Ji Jiang
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of MA41562A1 publication Critical patent/MA41562A1/fr
Publication of MA41562B1 publication Critical patent/MA41562B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La présente invention concerne des composés de formule (i), dans laquelle a, x et y sont tels que définis dans la spécification, et des compositions comprenant l'un quelconque de ces nouveaux composés. Ces composés sont des agonistes d'apj qui peuvent être utilisés en tant que médicaments.
MA41562A 2015-06-03 2016-06-02 Agonistes d'apj 4-hydroxy-3-(heteroaryl)pyridine-2-one a utiliser dans le traitement de troubles cardio-vasculaires MA41562B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562170215P 2015-06-03 2015-06-03
PCT/US2016/035482 WO2016196771A1 (fr) 2015-06-03 2016-06-02 Agonistes d'apj 4-hydroxy-3-(hétéroaryl)pyridine-2-one à utiliser dans le traitement de troubles cardio-vasculaires

Publications (2)

Publication Number Publication Date
MA41562A1 MA41562A1 (fr) 2018-05-31
MA41562B1 true MA41562B1 (fr) 2019-05-31

Family

ID=56131647

Family Applications (1)

Application Number Title Priority Date Filing Date
MA41562A MA41562B1 (fr) 2015-06-03 2016-06-02 Agonistes d'apj 4-hydroxy-3-(heteroaryl)pyridine-2-one a utiliser dans le traitement de troubles cardio-vasculaires

Country Status (36)

Country Link
US (3) US10011594B2 (fr)
EP (2) EP3530660A1 (fr)
JP (2) JP6483288B2 (fr)
KR (1) KR102066336B1 (fr)
CN (1) CN107922401B (fr)
AR (1) AR104884A1 (fr)
AU (1) AU2016270903B2 (fr)
CA (1) CA2988147C (fr)
CL (1) CL2017003055A1 (fr)
CO (1) CO2017013229A2 (fr)
CY (1) CY1121938T1 (fr)
DK (1) DK3303330T3 (fr)
EA (1) EA034912B1 (fr)
ES (1) ES2739526T3 (fr)
HK (1) HK1247915B (fr)
HR (1) HRP20191327T1 (fr)
HU (1) HUE045546T2 (fr)
IL (1) IL255951B (fr)
LT (1) LT3303330T (fr)
MA (1) MA41562B1 (fr)
ME (1) ME03474B (fr)
MX (1) MX378998B (fr)
MY (1) MY189453A (fr)
NZ (1) NZ738563A (fr)
PE (1) PE20180506A1 (fr)
PH (1) PH12017502158B1 (fr)
PL (1) PL3303330T3 (fr)
PT (1) PT3303330T (fr)
RS (1) RS59220B1 (fr)
SI (1) SI3303330T1 (fr)
SM (1) SMT201900427T1 (fr)
TN (1) TN2017000503A1 (fr)
TW (1) TWI672299B (fr)
UY (1) UY36705A (fr)
WO (1) WO2016196771A1 (fr)
ZA (1) ZA201708191B (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016263564B2 (en) 2015-05-20 2019-12-05 Amgen Inc. Triazole agonists of the APJ receptor
CA2988147C (fr) * 2015-06-03 2023-06-13 Bristol-Myers Squibb Company Agonistes d'apj 4-hydroxy-3-(heteroaryl)pyridine-2-one a utiliser dans le traitement de troubles cardio-vasculaires
PE20181197A1 (es) 2015-10-14 2018-07-23 Bristol Myers Squibb Co 2,4-dihidroxi-nicotinamidas como agonistas del receptor de apelina (apj)
BR112018010720A8 (pt) 2015-12-04 2019-02-26 Bristol Myers Squibb Co agonistas do receptor de apelina e métodos de uso
ES2854733T3 (es) * 2015-12-16 2021-09-22 Bristol Myers Squibb Co Heteroarilhidroxipirimidinonas como agonistas del receptor APJ
TWI744301B (zh) * 2016-03-24 2021-11-01 美商必治妥美雅史谷比公司 做為apj促效劑之6-羥基-4-側氧-1,4-二氫嘧啶-5-甲醯胺
US9988369B2 (en) 2016-05-03 2018-06-05 Amgen Inc. Heterocyclic triazole compounds as agonists of the APJ receptor
ES2844184T3 (es) * 2016-06-14 2021-07-21 Bristol Myers Squibb Co 4-hidroxi-3-sulfonilpiridin-2(1H)-onas como agonistas del receptor de APJ
WO2017218633A1 (fr) 2016-06-14 2017-12-21 Bristol-Myers Squibb Company 6-hydroxy-5-(phényl/hétéroarylsulfonyl) pyrimidin-4(1h)-one utilisée en tant qu'agonistes de l'apj
CN110072850B (zh) * 2016-10-14 2023-07-21 百时美施贵宝公司 3-磺酰基-5-氨基吡啶-2,4-二醇apj激动剂
US10689367B2 (en) 2016-11-16 2020-06-23 Amgen Inc. Triazole pyridyl compounds as agonists of the APJ receptor
WO2018097944A1 (fr) 2016-11-16 2018-05-31 Amgen Inc. Composés de triazole furane utilisés en tant qu'agonistes du récepteur apj
US11046680B1 (en) 2016-11-16 2021-06-29 Amgen Inc. Heteroaryl-substituted triazoles as APJ receptor agonists
US11191762B2 (en) 2016-11-16 2021-12-07 Amgen Inc. Alkyl substituted triazole compounds as agonists of the APJ Receptor
US10906890B2 (en) 2016-11-16 2021-02-02 Amgen Inc. Triazole phenyl compounds as agonists of the APJ receptor
WO2018093577A1 (fr) 2016-11-16 2018-05-24 Amgen Inc. Composés de triazole à substitution cycloalkyle en tant qu'agonistes du récepteur apj
WO2018165520A1 (fr) 2017-03-10 2018-09-13 Vps-3, Inc. Composés inhibiteurs de métalloenzymes
MA50509A (fr) 2017-11-03 2021-06-02 Amgen Inc Agonistes de triazole fusionnés du récepteur apj
MA52487A (fr) 2018-05-01 2021-03-10 Amgen Inc Pyrimidinones substituées en tant qu'agonistes du récepteur apj
CN109704981B (zh) * 2019-02-16 2022-01-28 安徽诺全药业有限公司 取代合成(z)-3-氨基-2-(2-氟-3-甲氧基苯基)-2-丁烯酸乙酯的方法
CN109704980B (zh) * 2019-02-16 2022-05-13 安徽大学 一种(z)-3-氨基-2-(2-氟-3-甲氧基苯基)-2-丁烯酸乙酯的制备方法
CN109734616B (zh) * 2019-02-16 2022-05-13 安徽诺全药业有限公司 两步法合成(z)-3-氨基-2-(2-氟-3-甲氧基苯基)-2-丁烯酸乙酯的方法
WO2021021979A2 (fr) 2019-07-30 2021-02-04 Eikonizo Therapapeutics, Inc. Inhibiteurs de hdac6 et leurs utilisations
EP4504190A4 (fr) 2022-04-08 2026-03-25 Eikonizo Therapeutics Inc Inhibiteurs d'oxadiazole hdac6 et leurs utilisations
WO2024148104A1 (fr) 2023-01-03 2024-07-11 BioAge Labs, Inc. Polythérapie d'agoniste du récepteur d'apeline et d'agoniste du récepteur de glp-1 pour le traitement d'une maladie ou d'une affection associée à une prise de poids
WO2025213190A1 (fr) 2024-04-05 2025-10-09 BioAge Labs, Inc. Méthodes de traitement d'une maladie ou d'une affection associée à une prise de poids
WO2025251084A1 (fr) 2024-05-31 2025-12-04 BioAge Labs, Inc. Méthodes de traitement d'une maladie ou d'un état associé à un gain de poids

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1001159A (en) 1910-07-25 1911-08-22 Elizabeth Nielsen Skirt-gage.
GB1472257A (en) 1973-09-10 1977-05-04 Christiaens Sa A Derivative of 4-hydroxy-5-azacoumarin
US4866182A (en) 1988-02-18 1989-09-12 Merrell Dow Pharmaceuticals Inc. Cardiotonic alkanoyl and aroyl oxazolones
US5338740A (en) 1993-07-13 1994-08-16 Pfizer Inc. Angiotensin II receptor antagonists
JP3795305B2 (ja) 1999-07-19 2006-07-12 田辺製薬株式会社 医薬組成物
CA2438991C (fr) 2001-02-21 2010-08-17 Nps Pharmaceuticals, Inc. Composes heteropolycycliques et leur utilisations en tant qu'antagonistes des recepteurs metabotropiques du glutamate
EA006154B1 (ru) 2001-03-28 2005-10-27 Пфайзер Инк. N-фенпропилциклопентил-замещенные производные глутарамида в качестве nep ингибиторов при fsad
CA2459224C (fr) 2001-09-03 2012-05-08 Takeda Chemical Industries, Ltd. Derives de 1,3-benzothiazinone et leurs utilisations
JP2005170790A (ja) 2002-01-09 2005-06-30 Ajinomoto Co Inc Ｎ−アルキルスルフォニル置換アミド誘導体
JP2005162612A (ja) 2002-01-09 2005-06-23 Ajinomoto Co Inc アシルスルホンアミド誘導体
ES2334990T3 (es) * 2002-02-14 2010-03-18 Pharmacia Corporation Piridinonas sustituidas como moduladores de p38 map quinasa.
US20040147561A1 (en) * 2002-12-27 2004-07-29 Wenge Zhong Pyrid-2-one derivatives and methods of use
US20090048301A1 (en) 2003-07-09 2009-02-19 Imclone Systems Incorporated Heterocyclic compounds and their use as anticancer agents
US20060004001A1 (en) 2004-02-27 2006-01-05 Merz Pharma Gmbh & Co., Kgaa Tetrahydroquinolones and their use as modulators of metabotropic glutamate receptors
PE20060285A1 (es) * 2004-03-30 2006-05-08 Aventis Pharma Inc Piridonas sustituidas como inhibidores de pol(adp-ribosa)-polimerasa (parp)
CN1960969B (zh) 2004-04-01 2012-03-28 伊莱利利公司 组胺h3受体药物、其制备方法及治疗用途
JP5020073B2 (ja) 2004-06-18 2012-09-05 ミレニアム ファーマシューティカルズ インク． 第Ｘａ因子阻害剤
WO2006019833A1 (fr) 2004-07-26 2006-02-23 Eli Lilly And Company Derives d'oxazole en tant qu'agents de recepteur d'histamine h3, preparation et utilisations therapeutiques
EP1655283A1 (fr) 2004-11-08 2006-05-10 Evotec OAI AG Inhibiteurs de 11béta-HSD1
WO2006123165A2 (fr) * 2005-05-19 2006-11-23 Astex Therapeutics Limited Composes pharmaceutiques
WO2007023242A1 (fr) 2005-08-24 2007-03-01 Merz Pharma Gmbh & Co. Kgaa Tétrahydroquinolinones et leur usage en tant que modulateurs des récepteurs de glutamate métabotropiques
DK1984353T3 (en) 2006-01-23 2016-03-14 Amgen Inc Aurorakinasemodulatorer and method of use
JP2007314516A (ja) 2006-04-25 2007-12-06 Daiichi Sankyo Co Ltd ２以上の置換基を有するベンゼン化合物を含有する医薬
AU2007281212B8 (en) 2006-08-03 2013-02-28 Trustees Of Tufts College Non-flushing niacin analogues, and methods of use thereof
EP2099768A2 (fr) 2006-08-04 2009-09-16 Praecis Pharmaceuticals Incorporated Agonistes du recepteur de sphingosine-1-phosphate
EP1894924A1 (fr) 2006-08-29 2008-03-05 Phenex Pharmaceuticals AG Composés hétérocycliques de liason du FXR
CN101547694A (zh) 2006-12-01 2009-09-30 诺瓦提斯公司 用于促进生理性心脏肥大的蛋白酪氨酸磷酸酶抑制剂
EP2142547A1 (fr) 2007-03-28 2010-01-13 NeuroSearch A/S Dérivés de purinyle et leur utilisation en tant que modulateurs des canaux potassiques
EP2674417A3 (fr) * 2007-11-21 2014-04-09 Decode Genetics EHF Inhibiteurs de pde4 biaryle pour le traitement de l'inflammation
EP2254563A2 (fr) 2008-01-25 2010-12-01 Torrent Pharmaceuticals Ltd. Combinaisons pharmaceutiques
AU2009233711B2 (en) 2008-04-09 2015-02-12 Infinity Pharmaceuticals, Inc Inhibitors of fatty acid amide hydrolase
AU2009253046A1 (en) 2008-05-30 2009-12-03 Foster Wheeler Energia Oy Method of and system for generating power by oxyfuel combustion
WO2010002933A1 (fr) 2008-06-30 2010-01-07 Cylene Pharmaceuticals, Inc. Composés d'oxindole
JP5535931B2 (ja) 2008-10-27 2014-07-02 武田薬品工業株式会社 二環性化合物
CN102203117A (zh) * 2008-11-04 2011-09-28 安科治疗公司 Apj受体化合物
RU2012116207A (ru) 2009-09-24 2013-10-27 Ф.Хоффманн-Ля Рош Аг Производные индола в качестве модуляторов crac
AU2010299928A1 (en) 2009-09-24 2012-02-02 F. Hoffmann-La Roche Ag Heterocyclic antiviral compounds
WO2011062955A2 (fr) 2009-11-18 2011-05-26 University Of Massachusetts Composés pour la modulation de tlr2
CA2783801A1 (fr) 2009-12-18 2011-06-23 Activesite Pharmaceuticals, Inc. Promedicaments d'inhibiteurs de la kallicreine plasmatique
CN102241621A (zh) 2010-05-11 2011-11-16 江苏恒瑞医药股份有限公司 5,5-双取代-2-亚氨基吡咯烷类衍生物、其制备方法及其在医药上的应用
WO2011148956A1 (fr) 2010-05-24 2011-12-01 トーアエイヨー株式会社 Dérivé d'imidazole condensé
WO2012040532A1 (fr) * 2010-09-24 2012-03-29 Bristol-Myers Squibb Company Composés oxadiazoles substitués et leur utilisation en tant qu'agonistes du s1p1
JPWO2012074022A1 (ja) 2010-12-01 2014-05-19 旭硝子株式会社 イリジウムカチオン錯体および発光組成物
JP2014514257A (ja) 2011-03-03 2014-06-19 ユニバーシテーテ デス ザールランデス 選択的１７ベータ−ヒドロキシステロイドデヒドロゲナーゼ２型阻害剤としてのビアリール誘導体
WO2012142308A1 (fr) 2011-04-13 2012-10-18 Activesite Pharmaceuticals, Inc. Promédicaments d'inhibiteurs de la kallicréine plasmatique
EP2709609B1 (fr) 2011-05-17 2017-10-04 Shionogi & Co., Ltd. Composés hétérocycliques
BR112014015553B1 (pt) 2011-12-23 2020-02-27 Basf Se Compostos de isotiazolina, método de preparação de compostos, composição agrícola ou veterinária, usos de um composto e método para proteger plantas
US9399638B2 (en) * 2012-05-02 2016-07-26 Lupin Limited Substituted pyridine compounds as CRAC modulators
BR112014027133A2 (pt) 2012-05-09 2017-06-27 Basf Se compostos, composição agrícola ou veterinária, método para o controle das pragas de invertebrados, material de propagação dos vegetais e método para o tratamento ou proteção de um animal.
WO2013184202A1 (fr) 2012-06-08 2013-12-12 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Inhibiteurs de fbxo-3
US20160008339A1 (en) 2012-07-02 2016-01-14 Max-Delbruck-Centrum Fur Molekulare Medizin Psoralen derivatives for preventing or treating heart failure or cardiac hypertrophy
CN103570625A (zh) 2012-07-19 2014-02-12 南京英派药业有限公司 N-(3-杂芳基芳基)-4-芳基芳基甲酰胺和类似物作为Hedgehog通路抑制剂及其应用
US20140073634A1 (en) 2012-08-24 2014-03-13 Institute For Applied Cancer Science/The University of Texas MD Anderson Cancer Center Heterocyclic modulators of hif activity for treatment of disease
ES2623528T3 (es) * 2012-09-21 2017-07-11 Sanofi Derivados de amida de ácido benzoimidazolcarboxílico para tratar enfermedades metabólicas o cardiovasculares
WO2014062938A1 (fr) 2012-10-19 2014-04-24 Bristol-Myers Squibb Company Modulateurs du récepteur gamma orphelin associé aux rétinoïdes (rory)
AU2014228822A1 (en) 2013-03-15 2015-10-01 Memorial Sloan-Kettering Cancer Center HSP90-targeted cardiac imaging and therapy
WO2015017305A1 (fr) 2013-07-31 2015-02-05 Merck Sharp & Dohme Corp Inhibiteurs du canal potassique médullaire externe rénal
JP6199197B2 (ja) 2014-02-07 2017-09-20 花王株式会社 ポリオキシアルキレンアルキルエーテルカルボン酸塩の製造方法
JP2017071553A (ja) 2014-02-25 2017-04-13 味の素株式会社 ヘテロ原子−メチレン−ヘテロ環構造を有する新規化合物
AU2015233558A1 (en) 2014-03-20 2016-09-01 Bayer Pharma Aktiengesellschaft Novel compounds
JP6552061B2 (ja) 2014-06-10 2019-07-31 サンフォード−バーンハム メディカル リサーチ インスティテュート 代謝型グルタミン酸受容体の負のアロステリックモジュレーター（ｎａｍｓ）とその使用
AU2016263564B2 (en) 2015-05-20 2019-12-05 Amgen Inc. Triazole agonists of the APJ receptor
CA2988147C (fr) 2015-06-03 2023-06-13 Bristol-Myers Squibb Company Agonistes d'apj 4-hydroxy-3-(heteroaryl)pyridine-2-one a utiliser dans le traitement de troubles cardio-vasculaires
KR101711744B1 (ko) 2015-07-16 2017-03-02 경희대학교 산학협력단 옥사디아졸 유도체, 이의 제조방법 및 이를 포함하는 전자수송층
PE20181197A1 (es) 2015-10-14 2018-07-23 Bristol Myers Squibb Co 2,4-dihidroxi-nicotinamidas como agonistas del receptor de apelina (apj)
EP3380970B1 (fr) 2015-11-24 2023-01-04 Sanford Burnham Prebys Medical Discovery Institute Nouveaux dérivés azolés comme agoniste du récepteur de l'apéline
BR112018010720A8 (pt) 2015-12-04 2019-02-26 Bristol Myers Squibb Co agonistas do receptor de apelina e métodos de uso
PE20190258A1 (es) 2015-12-09 2019-02-25 Res Triangle Inst Antagonistas del receptor de la apelina (apj) mejorados y usos de los mismos
ES2854733T3 (es) 2015-12-16 2021-09-22 Bristol Myers Squibb Co Heteroarilhidroxipirimidinonas como agonistas del receptor APJ
TWI744301B (zh) 2016-03-24 2021-11-01 美商必治妥美雅史谷比公司 做為apj促效劑之6-羥基-4-側氧-1,4-二氫嘧啶-5-甲醯胺
ES2844184T3 (es) 2016-06-14 2021-07-21 Bristol Myers Squibb Co 4-hidroxi-3-sulfonilpiridin-2(1H)-onas como agonistas del receptor de APJ
WO2017218633A1 (fr) 2016-06-14 2017-12-21 Bristol-Myers Squibb Company 6-hydroxy-5-(phényl/hétéroarylsulfonyl) pyrimidin-4(1h)-one utilisée en tant qu'agonistes de l'apj
CN110072850B (zh) 2016-10-14 2023-07-21 百时美施贵宝公司 3-磺酰基-5-氨基吡啶-2,4-二醇apj激动剂

Also Published As

Publication number Publication date
JP6483288B2 (ja) 2019-03-13
ME03474B (fr) 2020-01-20
WO2016196771A1 (fr) 2016-12-08
IL255951B (en) 2021-06-30
CN107922401A (zh) 2018-04-17
PH12017502158B1 (en) 2022-04-27
ES2739526T3 (es) 2020-01-31
NZ738563A (en) 2019-09-27
US10336739B2 (en) 2019-07-02
CO2017013229A2 (es) 2018-03-28
HK1247915B (en) 2020-04-24
CL2017003055A1 (es) 2018-05-25
CY1121938T1 (el) 2020-10-14
AU2016270903A1 (en) 2018-01-18
EA201792548A1 (ru) 2018-06-29
EA034912B1 (ru) 2020-04-06
SMT201900427T1 (it) 2019-09-09
BR112017024846A2 (pt) 2018-08-07
PL3303330T3 (pl) 2019-10-31
EP3530660A1 (fr) 2019-08-28
KR102066336B1 (ko) 2020-01-14
TN2017000503A1 (en) 2019-04-12
PE20180506A1 (es) 2018-03-09
SI3303330T1 (sl) 2019-08-30
RS59220B1 (sr) 2019-10-31
CA2988147C (fr) 2023-06-13
MX378998B (es) 2025-03-11
IL255951A (en) 2018-01-31
HRP20191327T1 (hr) 2019-11-01
CN107922401B (zh) 2021-04-16
US20190263791A1 (en) 2019-08-29
US10011594B2 (en) 2018-07-03
EP3303330A1 (fr) 2018-04-11
CA2988147A1 (fr) 2016-12-08
DK3303330T3 (da) 2019-08-05
US20160355507A1 (en) 2016-12-08
ZA201708191B (en) 2019-07-31
US20180273518A1 (en) 2018-09-27
AU2016270903B2 (en) 2020-04-30
PT3303330T (pt) 2019-08-05
JP2019094345A (ja) 2019-06-20
MY189453A (en) 2022-02-14
JP2018516928A (ja) 2018-06-28
MA41562A1 (fr) 2018-05-31
EP3303330B1 (fr) 2019-05-01
TWI672299B (zh) 2019-09-21
PH12017502158A1 (en) 2018-06-11
HUE045546T2 (hu) 2020-01-28
MX2017014956A (es) 2018-04-13
LT3303330T (lt) 2019-08-12
KR20180014422A (ko) 2018-02-08
TW201708214A (zh) 2017-03-01
UY36705A (es) 2016-11-30
AR104884A1 (es) 2017-08-23

Similar Documents

Publication Publication Date Title
MA41562A1 (fr) Agonistes d'apj 4-hydroxy-3-(heteroaryl)pyridine-2-one a utiliser dans le traitement de troubles cardio-vasculaires
MA51530B1 (fr) Composés cycliques fondus
MA44474B1 (fr) Inhibiteurs de la ferroportine
MA39783A (fr) Dérivés de quinoxaline utiles en tant que modulateurs de la fgfr kinase
WO2019035864A8 (fr) Activateurs de la pyruvate kinase destinés à être utilisés dans le traitement de troubles sanguins
MA42109B1 (fr) Amides hétérocycliques utilisés en tant qu'inhibiteurs de kinase
MA39554A3 (fr) Spirocycloheptanes utilisés en tant qu'inhibiteurs de rock
MA35342B1 (fr) Composés de-pipéridinyle utiles comme inhibiteurs de la tankyrase
MA45020A (fr) Dérivés sulfonamides aromatiques
MA50240A (fr) Modulateurs de la protéine régulatrice de la conductance transmembranaire de la fibrose kystique et procédés d'utilisation
MA47043B1 (fr) Composés indole carboxamides utiles comme inhibiteurs de kinase
MA43409B1 (fr) Composés polycycliques à utiliser en tant qu'inhibiteurs de la tyrosine kinase de bruton
MA38398A1 (fr) Composés biaryle amides en tant qu'inhibiteurs de kinase
MA42410B1 (fr) Oxystérols et leurs méthodes d'utilisation
MA37762B1 (fr) Composés n-aryltriazole utilisés comme antagonistes de lpar
MA40955A (fr) 2-amino-6-(difluorométhyl)-5,5-difluoro-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1
MA41185B1 (fr) Composés d'acide isoxazole hydroxamique comme inhibiteurs de lpxc
MA42397B1 (fr) 4-azaindoles substituées et leur utilisation comme modulatoeurs de la récepteur glun2b
MA38810A1 (fr) Inhibiteurs de rorc2 méthodes d'utilisation associées
MA39927B1 (fr) Inhibiteurs de glyt1 pour le traitement de troubles hématologiques
MA40366A (fr) Dérivés de tétrahydroquinoline à titre d'inhibiteurs des bromodomaines
MA39337A1 (fr) Modulateurs de pyrazines de gpr6
MA39253B1 (fr) Composés hétéroaryle bicycliques substitués utilisés comme agonistes de rxr
MA38410A1 (fr) Composés d'azétidinyloxyphénylpyrrolidine
MA38679A1 (fr) Modulateurs du récepteur de cxcr7